$64.88
Manufacturer: Germany
Treatment of advanced hormone receptor positive breast cancer in postmenopausal women.
Additive treatment of early-stage invasive breast cancer with positive hormone receptors in postmenopausal patients.
Additive treatment of early-stage hormone receptor-positive invasive breast cancer in postmenopausal patients treated with adjuvant tamoxifen for 2-3 years.
Description
Ingredients
active ingredient: anastrozole;
1 tablet contains 1.0 mg anastrozole;
excipients: lactose, microcrystalline cellulose, sodium starch (type A), magnesium stearate, colloidal silicon dioxide, hydroxypropyl methylcellulose, Opadry II White (lactose, hypromellose, titanium dioxide (E 171), polyethylene glycol).
Dosage form
Film-coated tablets.
Basic physical and chemical properties: white round biconvex film-coated tablets, without separating notch, with A1 embossed on one side.
Pharmacotherapeutic group
enzyme inhibitors. ATX code L02B G03.
Pharmacodynamics
Anastrozole is a potent and highly selective non-steroidal aromatase inhibitor. In postmenopausal women, estradiol is mainly produced by converting androstenedione to estrone in peripheral tissues using the aromatase enzyme. Estrone is further converted to estradiol. Reducing the level of estradiol has a therapeutic effect in women with breast cancer. In postmenopausal women, taking anastrozole at a daily dose of 1 mg leads to a decrease in estradiol levels by 80%. Anastrozole has no progestogenic and androgenic activity. Anastrozole in daily doses up to 10 mg does not affect the secretion of cortisol and aldosterone, measured before and after the standard ACTH stimulation test (ACTH). So, substitution of corticosteroids is not necessary.
Indications
Treatment of advanced hormone receptor positive breast cancer in postmenopausal women.
Additive treatment of early-stage invasive breast cancer with positive hormone receptors in postmenopausal patients.
Additive treatment of early-stage hormone receptor-positive invasive breast cancer in postmenopausal patients treated with adjuvant tamoxifen for 2-3 years.
Contraindications
Anastrozol Sandoz is contraindicated in patients:
- during pregnancy and lactation;
- with known hypersensitivity to anastrozole or other components of the drug.
Dosage and administration
Anastrozol Sandoz is taken orally.
Adult women, including elderly women – 1 tablet (1 mg) orally 1 time per day.
For early-stage hormone receptor-positive invasive breast cancer in postmenopausal women, the recommended duration of adjuvant endocrine treatment is 5 years.
Renal impairment: Patients with mild or moderate renal impairment do not require dose adjustment. The use of the drug Anastrozol Sandoz in patients with severely impaired renal function requires caution.
Impaired liver function: Patients with mild liver disease dose adjustment is not required. In patients with moderate to severe hepatic impairment, the drug should be used with caution.
Recent Reviews